Abstract

TRANSBIG comprises 28 world-class institutions in 11 countries. Each participating organization brings with it expertise that ranges from specialization in cutting-edge biomedical technologies and cancer treatment programs to representing patient groups and supporting cancer societies. Among its many strengths is the fact that TRANSBIG is linked to an already existing network of groups from around the world that conduct clinical breast cancer trials together – the Breast International Group (BIG).

Mission

The main objectives of TRANSBIG were:

- to accelerate the way laboratory discoveries for breast cancer “translate” into treatments for patients (translational research)

- to advance personalized treatment for breast cancer patients
to strengthen and facilitate collaboration in translational breast cancer research in Europe and internationally

**Consortium History**

2007 - **MindAct** Trial

TRANSBIG/MindAct Biobank

TRANSBIG traineeship programme

**Structure & Governance**

The consortium is governed by Breast International Group.

**Financing**

Funding from the European Commission under Framework Programme VI (FP6)

**Impact/Accomplishment**

Click [here](http://consortiapedia.fastercures.org) for a description of consortium accomplishments

**Links/Social Media Feed**
Points of Contact

Breast International Group (BIG)-aisbl
Blvd de Waterloo 121
B-1000 Brussels | Belgium
VAT BE 0468 176 240

Sponsors & Partners

59 MEMBER GROUPS COVERING 55+ COUNTRIES

Updated: 06/21/2017